Phase 3
Completed N=104
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
Source: ClinicalTrials.gov NCT00997204 ↗Enrolled (actual)
104
Serious AEs
0.0%
Results posted
Jul 2014
Primary outcomePrimary: Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant — 11; 6; 27 participants
Summary
This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant |
11; 6; 27 | — |
| SECONDARY Clinical Efficacy of Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant, Time to Symptom Relief Using VAS Score for a Single Primary Symptom by Patient Cohort |
2.0; 3.1; 2.0 | — |
Eligibility Criteria
Inclusion Criteria
Each patient must meet the following criteria to be enrolled in this study.
- Males and females 18 years of age at the time of informed consent
- Documented diagnosis of HAE Type I or II based on ALL of the following criteria:
- Family and/or medical history
- Characteristic attack manifestations, recurrent attacks
- Historical functional C1-INH <50% normal values
- Women of childbearing potential must use consistently and correctly a highly effective, adequate method of birth control (failure rate less than 1% per year) - sexual abstinence or have a vasectomised partner during the duration of the study. Hormonal contraception can be continued if verified by a physician that it doesn't affect the course of HAE attacks.
- Mental and physical condition allowing patients to complete baseline assessment, to self-administer icatibant and to follow other study procedures.
- Ability to provide signed written informed consent after all aspects of the study have been explained and discussed with the patient.
Exclusion Criteria
Patients who meet any of the following criteria will be excluded from the study.
- Participation in a clinical trial of another investigational medicinal product within the past month (except a previous icatibant study).
- Diagnosis of angioedema other than Type I or Type II HAE.
- Evidence of symptomatic coronary artery disease based on medical history, in particular, unstable angina pectoris or severe coronary heart disease.
- Congestive heart failure (NYHA Class 3 and 4).
- Stroke within the past 6 months.
- Treatment with angiotensin converting enzyme (ACE) inhibitor.
- Pregnancy and/or breast-feeding.
- In the opinion of the investigator: mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study.
- In the opinion of the investigator: unlikely to comply with the protocol, for example, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study for any reason.
- In the opinion of the investigator: inability to manage study medication or self-administration of an injection.
Data sourced from ClinicalTrials.gov (NCT00997204). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.